Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661544 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00661544: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00661544 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00661544, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
1. To evaluate the toxicity and safety of a combination of arsenic trioxide with ascorbic acid and high-dose Melphalan in patients with multiple myeloma 2. To evaluate the efficacy of a combination of arsenic trioxide with ascorbic acid and high-dose Melphalan in patients with multiple myeloma 3. To determine the effects of arsenic trioxide on melphalan pharmacokinetics
Interventions
- DRUG Melphalan
- DRUG Arsenic Trioxide
- DRUG Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661544
The ClinicalTrials.gov registry entry for NCT00661544 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Melphalan is the first listed.
NCT00661544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661544 about?
NCT00661544 is a clinical study titled "Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients". 1. To evaluate the toxicity and safety of a combination of arsenic trioxide with ascorbic acid and high-dose Melphalan in patients with multiple myeloma 2. To evaluate the efficacy of a combination of arsenic trioxide with ascorbic acid and high-dose Melphalan in patients with multiple myeloma 3. To...
What is the current status of trial NCT00661544?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2004-03. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00661544?
The interventions under investigation include: Melphalan (DRUG), Arsenic Trioxide (DRUG), Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT00661544?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.